Phase II study of pazopanib with weekly paclitaxel in refractory urothelial cancer.

被引：1
|
作者：
Srinivas, Sandy
Narayanan, Sujata
Harshman, Lauren Christine
Pachynski, Russell Kent
Lam, Anthony P.
Fan, Alice C.
Poushnejad, Shermeen
Haas, Denise
Vaishampayan, Ulka N.
机构：
[1] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
[2] Stanford Univ, Stanford, CA 94305 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Washington Univ, Sch Med, St Louis, MO USA
[5] Stanford Canc Inst, Stanford, CA USA
[6] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.294
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
294
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer
    Markman, M
    Hall, J
    Spitz, D
    Weiner, S
    Carson, L
    Van Le, L
    Baker, M
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (09) : 2365 - 2369
  • [22] Phase I/II study of carboplatin and weekly paclitaxel for advanced non-small cell lung cancer.
    Ohashi, N
    Arita, KI
    Daga, H
    Mito, A
    Nishino, R
    Moritani, C
    Nakamura, K
    Daido, K
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 687S - 687S
  • [23] Weekly paclitaxel in metastatic breast cancer patients: A phase II study
    Gori, S
    Mosconi, AM
    Basurto, C
    Cherubini, R
    De Angelis, V
    Tonato, M
    Colozza, M
    TUMORI, 2002, 88 (06) : 470 - 473
  • [24] A phase II study of nab-paclitaxel in refractory CIMP-high metastatic colorectal cancer.
    Overman, Michael J.
    Kee, Bryan K.
    Fogelman, David R.
    Eng, Cathy
    Sanchez, Eduardo Vilar
    Shroff, Rachna T.
    Dasari, Arvind
    Wolff, Robert A.
    Morris, Jeffrey
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [25] Phase I study of weekly vinorelbine in combination with weekly paclitaxel in adult patients with advanced refractory cancer
    Cohen, RB
    Mueller, SC
    Haden, K
    de Souza, P
    CANCER INVESTIGATION, 2000, 18 (05) : 422 - 428
  • [26] Phase II study of paclitaxel in patients with advanced gastric cancer.
    Horikoshi, N
    Yamaguchi, K
    Otani, T
    Takiuchi, H
    Sakata, Y
    Taguchi, T
    ANNALS OF ONCOLOGY, 2000, 11 : 66 - 66
  • [27] Phase II trial of weekly 1-hour paclitaxel (PAC) for metastatic breast cancer.
    Scuderi, C
    Crivellari, D
    Magri, MD
    Di Lauro, V
    Lombardi, D
    Paolello, C
    Spazzapan, S
    Veronesi, A
    ANNALS OF ONCOLOGY, 2000, 11 : 29 - 30
  • [28] Randomized phase II study comparing dose-escalated weekly paclitaxel versus standard dose weekly paclitaxel for patients with previously treated advanced gastric cancer.
    Shitara, Kohei
    Yuki, Satoshi
    Takahari, Daisuke
    Nakamura, Michio
    Kondo, Chihiro
    Tsuda, Takashi
    Kii, Takayuki
    Tsuji, Yasushi
    Utsunomiya, Setsuo
    Ichikawa, Daisuke
    Hosokawa, Ayumu
    Ishiguro, Atsushi
    Sakai, Daisuke
    Hironaka, Shuichi
    Oze, Isao
    Matsuo, Keitaro
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] The weekly triplet: Gemcitabine, carboplatine and paclitaxel as first line therapy for advanced urothelial cancer.
    Chahine, GY
    Kattan, JG
    Farhat, FS
    Nasr, FL
    Moukaddem, WT
    Tueini, EA
    Dagher, JE
    Younes, FC
    Ghosn, MG
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 432S - 432S
  • [30] Weekly cisplatin-epirubicin-paclitaxel in advanced breast cancer. A phase I study
    Frasci, G
    Comella, P
    Apicella, A
    D'Aiuto, G
    Thomas, R
    Capasso, I
    Di Bonito, M
    Piccolo, S
    Carteni, G
    Gravina, A
    Comella, G
    ANNALS OF ONCOLOGY, 1998, 9 : 98 - 98
12345